Appeal type: Medical necessity
Decision: Overturned

Diagnosis:  Idiopathic short stature (ISS)
Treatment: Norditropin
The insurer denied the Norditropin.
The determination is overturned.

The patient was diagnosed with idiopathic short stature (ISS). This request is for Norditropin. His growth hormone (GH) stimulation test with arginine and clonidine peaked at 15.3. His height velocity is reported to be 3.3 centimeters per year (cm/yr). His Insulin-like Growth Factor-1 (IGF-1) was 106 (range 84-382), then 111. His testes were at Tanner 1 as was pubic hair. The provider states "Zomacton is not available. Humatrope does not provide patient injection training, they are unable to travel here for instruction."
The patient's weight was 25.4 kilograms (kg). His height was 128.60 cm (-2.96 standard deviation score (SDS)) and then 130.81 cm (-3.13 SDS) with a height velocity over 8 months of 3.3 cm/yr.
His mother's height is 152.4 cm and his father's height is 167.64 cm and mid parental height is 166.52 cm (-1.44 SDS)
At issue is the medical necessity of the Norditropin.

The Norditropin is medically necessary.
The peer reviewed literature including consensus clinical guidelines, randomized controlled trials are summarized below:

Classic GH deficiency criteria are outlined in the consensus guidelines for the diagnosis and treatment of GH deficiency published by the Growth Hormone (GH) Research Society[1], the Lawson Wilkins Pediatric Endocrinology Society[2, 3], and the medical guidelines for GH use provided by the American Association of Clinical Endocrinologists[4]. The above referenced guidelines are the latest available guidelines from these respective societies. The diagnosis is based on height, height velocity, biochemical and sometimes radiological findings. The height and height velocity criteria based on consensus guidelines upon which a biochemical evaluation is to be initiated are 1) severe short stature, defined as a height more than 3 standard deviations (SD) below the mean; 2) height more than 1.5 SD below the mid parental height SD; 3) height more than 2 SD below the mean and a height velocity over 1 year (yr) more than 1 SD below the mean for chronological age, or a decrease in height SD of more than 0.5 over 1 yr in children over 2 yr of age; 4) in the absence of short stature, a height velocity more than 2 SD below the mean over 1 yr or more than 1.5 SD sustained over 2 yr. The biochemical criteria include low IGF1 or Insulin-like growth factor binding protein 3 (IGFBP3) or GH stimulation testing with a peak GH less than 10 nanograms per milliliter (ng/ml).
The patient did not meet biochemical criteria. Growth hormone stimulation testing peaked at greater than 10.

Growth hormone in the treatment of idiopathic short stature (ISS) is supported by randomized controlled trials and consensus guidelines [4-9]. Food and Drug Administration (FDA) approval for this indication is for "non-growth hormone-deficient short stature, defined by height SDS less than or equal to -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means."[10-13]
The patient had a pretreatment height less than or equal to -2.25 SD. The patient's height velocity is poor and bone age would not allow the patient to reach a normal adult height. The request therefore meets idiopathic short stature criteria.
The request is consistent with generally accepted standards of medical practice and is therefore medically necessary.